In the early hours of June 3, Beijing time, longevity technology startup NewLimit announced the completion of a $435 million Series C financing round. The investment was led by Founders Fund, the venture capital firm associated with Peter Thiel, while additional capital came from Abstract Ventures, Kleiner Perkins, NFDG, Eli Lilly Ventures, and Valor Equity Partners. New participants in this round included Thrive Capital, Greenoaks, and Quiet Capital. Data compiled by Woofun AI shows that NewLimit's valuation reached $3.1 billion in this transaction, representing a more than threefold increase compared to its valuation just one year prior. The company stated that following significant research milestones, it is now advancing its longevity medicine pipeline toward clinical trials, with the first drug targeting alcohol-related liver diseases expected to enter the trial phase next year. NewLimit emphasized that by reprogramming cell age, the goal of delaying or even reversing aging is becoming increasingly attainable.

One of NewLimit's co-founders is Brian Armstrong, the founder and CEO of Coinbase. In 2021, Armstrong partnered with former GV partner and bioengineer Blake Byers and stem cell biologist Jacob Kimmel to establish the company in southern San Francisco with an initial $110 million investment. Prior to the current Series C round, NewLimit had successfully completed three previous funding rounds. The company's official statement highlights its focus on developing drugs designed to extend healthy human lifespan. As people age, cellular functions decline, increasing susceptibility to disease; however, emerging scientific research suggests that the aging process can be reversed at the cellular level. NewLimit is leveraging these findings to create the first drugs capable of restoring youthful functions to aging cells, effectively using scientific methods to explore the possibility of extended life.

Although the scientific community has long acknowledged the link between aging and cellular decline, a precise method to rejuvenate cells remained elusive until 2006. That year, Japanese scientist Shinya Yamanaka discovered that activating a few specific transcription factors could reprogram adult cells into a youthful state resembling embryonic stem cells. This breakthrough, known as the 'Yamanaka Factors,' earned Yamanaka the Nobel Prize in Physiology or Medicine in 2012 and proved that cell age is not irreversible. NewLimit's efforts are built directly upon this discovery. The company states that its drugs aim to reprogram the epigenome of cells into a younger state by activating specific transcription factor genes. Woofun AI notes that while the reversal is scientifically possible, identifying the precise combination of transcription factors required to restore youthful functions across different cell types remains the core challenge of their work.

NewLimit's strategic approach involves starting with a specific disease to secure drug approval before expanding to broader applications. As noted, the company is currently advancing clinical trials for a drug targeting alcohol-related liver diseases. Jacob Kimmel, co-founder and CEO of NewLimit, explained that liver diseases can be viewed as a form of 'accelerated aging,' which simply speeds up the natural aging process experienced by everyone. This targeted strategy allows the company to navigate regulatory pathways while validating the underlying technology. The focus on liver disease serves as a critical proof of concept for the broader application of cell reprogramming in treating age-related conditions.

NewLimit is not the only technology company targeting the extension of human life. In 2022, Sam Altman invested $180 million in Retro Biosciences, a firm developing drugs to restore vitality to aging cells. Reports indicate that Retro Biosciences' valuation reached $1.8 billion last month.

Additionally, Altos Labs, which reportedly received funding from Jeff Bezos, began operations in 2022 with $3 billion in capital, and its total funding has since nearly doubled. Woofun AI analysis suggests that from Peter Thiel to Sam Altman to Jeff Bezos, the super-rich at the apex of the tech and wealth pyramid are the most active investors in this field. Peter Thiel has openly expressed a deep aversion to death, stating that death is humanity's greatest enemy yet is often treated as a natural law.

The willingness of these tech giants to invest billions of dollars is driven by a clear logic: when wealth and power reach their peak, time becomes the only enemy and the only luxury that cannot be purchased with money. Once sufficient capital is accumulated, the question of how to live longer becomes paramount.

This shift in focus from wealth accumulation to life extension represents a significant trend in the intersection of technology, finance, and biotechnology. The convergence of massive capital and advanced cellular research indicates that the pursuit of immortality is transitioning from theoretical science to a tangible, well-funded industrial endeavor.